HeartBeam Inc. BEAT Archives

FridayMar 13, 2026 9:00 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reports Q4 and Full-Year 2025 Results, Advances Commercialization and Clinical Development

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, reported financial and operational results for the fourth quarter and full year ended Dec. 31, 2025, highlighting progress toward commercialization following U.S. Food and Drug Administration ("FDA") 510(k) clearance of its 12-lead electrocardiogram ("ECG") synthesis software in December 2025. The company has initiated a limited market launch targeting concierge and preventive cardiology groups and secured its first commercial partnership with ClearCardio(TM), while also enrolling initial patients in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. Additional developments include completion…

MondayMar 09, 2026 9:45 am

HeartBeam Inc. (NASDAQ: BEAT) Moves Forward Focused on Advancing Portable, High-Fidelity Cardiac Monitoring

The company’s core innovation, the HeartBeam System, is positioned as the first cable-free, high-fidelity ECG system capable of capturing the heart’s electrical signals from three distinct directions. HeartBeam’s strategy is built around addressing a long-standing gap in cardiac care. Looking forward, HeartBeam is focused on advancing both its hardware and software platforms. HeartBeam (NASDAQ: BEAT) stands at a pivotal point in its development as a medical technology company focused on transforming how cardiac arrhythmias are detected, evaluated and monitored. Headquartered in Santa Clara, California, HeartBeam is building a platform designed starting with its FDA-cleared synthesized 12-lead ECG system to bring…

WednesdayMar 04, 2026 9:00 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Announces Commercial Partnership With ClearCardio as First Customer and Strategic Investor

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through advanced cardiac insights, announced a commercial partnership with ClearCardio(TM), a preventive cardiology practice serving thousands of patients through heart health screening and personalized prevention programs. ClearCardio will serve as HeartBeam’s first commercial customer and plans to make an investment in the company, underscoring strategic alignment. The staged rollout will integrate HeartBeam’s synthesized 12-lead ECG technology into ClearCardio’s cardiac prevention program for arrhythmia assessment, enabling patients to capture clinical-grade ECG readings from home using HeartBeam’s patented cable-free 3D ECG system. Structured as a Letter of Intent outlining subscription-based…

TuesdayMar 03, 2026 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) Upgraded to Buy as New Joseph Gunnar Report Raises Price Target on Commercialization Momentum

New report upgrades HeartBeam to buy, raises 12-month price target to $4, citing regulatory progress and company’s transition toward commercialization. Joseph Gunnar characterized the FDA clearance of HeartBeam’s 12-lead ECG synthesis software for arrhythmia assessment as a “critical regulatory milestone.” The research report underscores the company’s targeted go-to-market strategy. Equity research reports often serve as important barometers of shifting sentiment, offering investors detailed analysis of a company’s strategy, risks and growth potential. In a new research note, Joseph Gunnar & Co. upgraded HeartBeam (NASDAQ: BEAT) from Hold to Buy and raised its 12-month price target to $4 from $1, citing…

ThursdayFeb 12, 2026 10:30 am

HeartBeam Inc. (NASDAQ: BEAT) Highlighted Among Medical Device Innovators as FDA Clearances Set Tone for New Year

HeartBeam was included in a report published by Modern Healthcare that highlighted companies that achieved meaningful regulatory milestones or demonstrated forward momentum. HeartBeam’s technology is aligned with evolving regulatory and clinical priorities. In addition to being listed in the Modern Healthcare report, the company was also included in PatentVest’s “Total Cardiac Intelligence” report. HeartBeam (NASDAQ: BEAT) was recently recognized among a select group of medical device companies featured in a January industry roundup highlighting recent U.S. Food and Drug Administration (“FDA”) clearances and approvals across the sector. The recognition underscores HeartBeam’s progress as it advances a novel approach to cardiac diagnostics through…

FridayJan 09, 2026 12:25 pm

QualityStocksNewsBreaks – FDA Clearance for HeartBeam Inc. (NASDAQ: BEAT) Highlighted in Medical Device Approvals Roundup

HeartBeam (NASDAQ: BEAT) was among the medical device companies highlighted in a Jan. 8 report by Modern Healthcare by Lauren Dubinsky that outlined FDA clearances and approvals across the medical device sector. HeartBeam's 12-lead electrocardiogram synthesis software was cleared Dec. 8 to assess arrhythmias by converting heart signal data captured from 3 dimensions using the company’s portable, non-invasive recorder into a standard 12-lead ECG format suitable for remote clinical review. HeartBeam recently reinforced its technology leadership with recognition as a Global IP and Technology Leader in Portable Cardiac Diagnostics, ranking second worldwide and trailing only GE Healthcare, in 12-lead ECG innovation among 243 companies evaluated in PatentVest’s…

MondayJan 05, 2026 9:00 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Attend JP Morgan 2026 Annual Healthcare Conference

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through advanced cardiac insights, announced that it will attend the JP Morgan 2026 Annual Healthcare Conference taking place Jan. 12–15, 2026, at the Westin St. Francis Hotel in San Francisco, where Chief Executive Officer Robert Eno and Chief Financial Officer Timothy Cruickshank will be available Jan. 12–14 for off-site meetings with investors and potential commercialization and co-development partners. Discussions are expected to focus on the company’s recently announced 510(k) clearance from the U.S. Food and Drug Administration for its patented, cable-free 12-lead electrocardiogram synthesis software for arrhythmia assessment,…

WednesdayDec 17, 2025 2:03 pm

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Ranks Second Worldwide in 12-Lead ECG Innovation

HeartBeam (NASDAQ: BEAT), a medical-technology company developing advanced electrocardiogram solutions, was featured in a recent article that discussed its recognition as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest’s “Total Cardiac Intelligence” report. “The company ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only GE Healthcare. The recognition highlights HeartBeam’s growing influence in the next generation of cardiac monitoring technology,” reads the article. “HeartBeam’s ranking underscores the rapid maturation of the company’s proprietary synthesis-ECG system, which captures the heart’s electrical signals in three noncoplanar dimensions and synthesizes them into a 12-lead ECG. This unique…

WednesdayDec 10, 2025 9:10 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Secures FDA 510(k) Clearance for 12-Lead ECG Synthesis Software Following Successful Appeal

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, received FDA 510(k) clearance for its 12-lead ECG synthesis software for arrhythmia assessment after successfully appealing a prior NSE determination. The patented cable-free technology captures cardiac electrical signals in three non-coplanar dimensions to generate a synthesized 12-lead ECG that can be reviewed remotely by a board-certified cardiologist, enabling patients to capture meaningful ECG data wherever symptoms occur. With clearance in hand, HeartBeam plans a limited U.S. launch in early 2026 with select cardiology groups, alongside advancing programs in heart attack detection, development of an on-demand…

MondayDec 01, 2025 9:15 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Outlines Regulatory Strategy After NSE Decision on ECG Synthesis Software

HeartBeam (NASDAQ: BEAT), a medical technology company developing personalized cardiac-care insights, detailed its strategy following receipt of a Not Substantially Equivalent decision for its 510(k) submission covering its 12-lead ECG Synthesis Software. The Company has been in active discussions with FDA review staff, which have signaled willingness to work toward a constructive resolution. HeartBeam said its VALID-ECG clinical study met endpoints and that remaining FDA concerns may be resolved through revised labeling. To advance the process, the Company plans to pursue multiple parallel paths—including a formal appeal or a 510(k) resubmission—and believes recent interactions indicate a viable path forward under…

Site Search

Company Search

Tag: HeartBeam Inc. BEAT